文献速递胸部肿瘤放疗

不可手术III期非小细胞肺癌的化放疗联合免疫治疗:免疫学原理与当前临床试验

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.
PubMed 文献 · Radiat Oncol · 2020-07-09

本文综述了不可手术III期非小细胞肺癌(NSCLC)化放疗联合免疫治疗(化放疗免疫治疗)的免疫学原理和当前临床试验。临床前研究表明免疫检查点抑制剂(ICI)与放疗联合可协同提高肿瘤控制概率。在不可手术III期NSCLC中,同步铂类化放疗后使用PD-L1抑制剂度伐利尤单抗巩固治疗可显著改善无进展生存和总生存,已成为新的治疗标准。

要点

  • 临床前研究显示ICI与放疗联合可协同提高肿瘤控制概率。
  • 不可手术III期NSCLC中,同步铂类化放疗后度伐利尤单抗巩固治疗改善无进展生存和总生存。
  • 该三模式治疗已成为新治疗标准,下一步需开发预测生物标志物以优化患者选择。

核心结论

  • 不可手术III期NSCLC中,同步铂类化放疗后度伐利尤单抗巩固治疗已成为新的治疗标准。

研究设计与样本

  • 本文为综述,讨论免疫学原理和当前研究化放疗免疫治疗的临床试验。

主要发现

  • 临床前研究表明ICI与放疗联合可协同提高肿瘤控制概率。
  • 在晚期NSCLC中,靶向免疫检查点通路比常规化疗毒性更低且缓解更持久。
  • 不可手术III期NSCLC中,同步铂类化放疗后度伐利尤单抗巩固治疗显著改善无进展生存和总生存。

临床怎么用

  • 不可手术III期NSCLC患者完成同步铂类化放疗后,可考虑度伐利尤单抗巩固治疗。
  • 需开发预测生物标志物并改进患者选择和监测,以识别最可能从该多模式治疗中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Käsmann L, Eze C, Taugner J, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 2020. PMID: 32646443. doi:10.1186/s13014-020-01595-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。